Collegium Pharma (NASDAQ: COLL) reported Q1 EPS of ($0.39), $1.29 worse than the analyst estimate of $0.90. Revenue for the quarter came in at $83.8 million versus the consensus estimate of $78.88 million.

GUIDANCE:

Collegium Pharma sees FY2022 revenue of $450-465 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.